Ngm Biopharmaceuticals, Inc.

Shaman Pharmaceuticals, Inc.

Other

Metabolex, Inc.

Amgen Inc.

Diatex, Inc.

Jian Luo

Lei Ling

Kenneth L Luskey

Julio Cesar Medina

Jonathan B Houze

Liusheng Zhu

Jiwen Liu

Hui Tian

Yingcai Wang

Diana M Fort

Jeffrey D Reagan

Zhihua Ma

Rajiv Sharma

Donald E Bierer

Michael J Schmitt

Jian Zhang

Jinqian Liu

Stephen J Shuttleworth

Steven Row King

Daniel C H Lin

Michelle Akerman

Wei Qiu

Ying Sun

Wayne D Inman

Reimar C Bruening

Alexander Mark Depaoli

Joseph L Evans

Xiaohui Du

Wang Shen

Zuchun Zhao

Ming Yu

Zice Fu

Paul John Dransfield

Sean P Brown

Vatee Pattaropong

Gayathri Swaminath

An-Rong Li

Todd J Kohn

Jie Zhang

Marc Vimolratana

YuMei Xiong

Xian Yun Jiao

Yongli Su

SuJen Lai

Margrit Schwarz

Yong-Jae Kim

Atul S Khandwala

Qiong Cao

Hui Chang Wu

Christopher D Mendez

Jolad D Shivanand

Rosa P Ubillas

Thomas J Carlson

Daniel Lin

Li Yang

Jinqain Liu

Kenneth L Lusky

The invention relates to methods of using variants of fibroblast growth factor 19 (FGF19) for treating primary biliary cirrhosis.

Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject

Provided herein are methods of using 7&#x3b1;-hydroxy-4-cholesten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders

The invention relates to methods of using variants of fibroblast growth factor 19 (FGF19) for reducing bile acid synthesis in a subject having cirrhosis.

Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis

Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FG-F19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.

Methods of using variants of FGF19 polypeptides for the treatment of pruritus

A principal objective of the present invention is to provide system for temperately retaining eyeglasses on a user's headwear. This objective is achieved by incorporating magnetic elements on the headwear and eyewear of the user. In one embodiment of the present invention, two magnetic elements are attached to the inside surfaces of the two temple arms of a pair of eyeglasses. Another two magnetic elements are attached to the two sides of a hat permanently or removably. The polarities of the magnetic elements are arranged in such way that when the two temple arms of the eyeglasses are placed in contact to the two sides of the hat from the outside of the hat, the magnetic elements on the eyeglasses and the magnetic elements on the headwear form magnetic element coupling pairs with attraction magnetic force. When the eyeglasses are not in use and need to be temporarily stored away from the eyes, the user can lift them to the crown or above the brim of the hat. The corresponding magnetic element coupling pairs will attach the temple arms of the eyeglasses to the side of the hat.

System and method for securing eyewear

Provided herein are methods of using 7a-hydroxy-4-cholsten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasis

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasis

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitis

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitis

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption

Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases

The present invention provides the use of (&#x2212;) (3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.

Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia

Growing community of inventors

Albany, CA, United States of America

Jian Luo